sur DocMorris AG (isin : CH0042615283)
DocMorris Reports 6.7% Growth in 2024 with Strong Rx Revenue Surge
DocMorris AG announced a 6.7% growth in revenue for 2024, reaching CHF 1,085 million. Growth was driven across all divisions, with notable success in the Rx segment. Rx revenue soared by 16.6% in Q4 and the number of new Rx customers increased fivefold. OTC revenues also matched overall growth at 6.7%.
In Germany, key market revenue rose by 6.9%, totaling CHF 1,021.9 million. This was complemented by significant Rx customer activity and a strong performance by TeleClinic, which doubled its revenue to approximately CHF 11 million. The Europe segment, focusing on Spain, France, and Portugal, saw a 3.6% revenue increase.
Despite challenges, the company attained a cash position of CHF 95 million by year-end, alongside the successful execution of its break-even programme and strategic streamlining initiatives.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de DocMorris AG